GPCR Agonist Market was valued at USD 2.70 billion in 2019 and expected to reach at a CAGR 6.9% by 2030.
GPCR Agonist is commonly referred as -Protein Coupled receptors which have an important role in medically-relevant pathways. These are used for the treatment of various diseases such as cancer autoimmune diseases , Central Nervous System (CNS) diseases, and cardiovascular system diseases .Also, GPCR agonist are used for the CNS diseases like Alzheimer's disease, Parkinson's disease and Huntington’s disease which are associated with old age population.
Increase in incidences of various diseases like cancer, autoimmune diseases, Central Nervous System Diseases (CNS) is expected to boost the global GPCR agonist market growth. Furthermore, increase in effective identification of pharmaceutically relevant drug candidates is expected to propel the growth of global GPCR agonist market growth. Moreover in research and development in drug discovery is expected to fuel the global GPCR agonist market growth during this forecast period. In addition to that, rise in number of allosteric modules, biased diagnosis, and biological drugs will accelerate the demand for global GPCR Agonist market growth.
However, unavailability of treatment opportunities and lack of drug development research in the underdeveloped countries are expected to hamper global GPCR agonist market growth.
Global GPCR Agonist Market is segmented into product type such as Instruments (Microfluidicdroplet Generator, Single-Inlet Microfluidic Device, Air Compressor, Micromanipulator, Confocal Microscope, Mitos-P-Pump, and Microplate Fluorometer), Reagents and Chemicals (Cell Line, Repoter Gene, and Media), and Kits, by technology such as High-Throughput Functional Cell Based Assay, Fluorescence Microscopy Analysis, Triple-quadrupole mass spectroscopy, Luciferaase Assay, Real-Time Bioluminescence, Resource Energy Transfer (BRET) Assay, Reporter gene Assay, cAMP Assay, cGMP Assay, and High Thtroughput Screening (HTS) Assay. Further, Global GPCR Agonist Market is segmented into application such as Cancer Research, Cardiovascular System Diseases, Central Nervous System Diseases, Drug Discovery, and Others, by end user such as Academic Institutes and Research Institutes, Clinical Research Organizations, and Biophrmaceutical Companies.
Also, Global GPCR Agonist Market is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa
Various key players are discussed in this report such as European Collection of Cell Culture, Clontech Laboratries, Inc.,Nacalai Tesque, GE Healthcare, Thermo Fisher Scientific, Nano-Glo™ Luciferase Assay System, Promega, Fluoroskan Ascent, Sigma-Aldrich, Wako Pure Chemical Industries, Zymo Research, Clontech Laboratries, Inc.,and Drummond Scientific Co.
Global GPCR Agonist Market
1. Executive Summary 1.1. Market Taxonomy 2. Global GPCR Agonist Market Demand (in Value or Size in US$ Mn) Analysis and Forecast 3. Market Background 3.1. Forecast Factor 3.2. Market Dynamics 3.2.1. Drivers 3.2.2. Challenges 3.2.3. Trends 4. Global GPCR Agonist Market Snapshot 5. Global GPCR Agonist Market Analysis, By Product Type 5.1. Y-o-Y Growth Comparison, By Product Type 5.2. Global GPCR Agonist Market Share Analysis, By Product Type 5.3. Global GPCR Agonist Market Size and Forecast, By Product Type 5.3.1 Instruments 5.3.1.1 Microfluidic droplet generator 5.3.1.2 Single –inlet microfludic device 5.3.1.3 Air Compressor 5.3.1.4Micromanipulator 5.3.1.5Confocal Microscope 5.3.1.6Mitos p pump 5.3.1.7Microplate Fluoremeter 5.3.2 Reagents and Chemicals 5.3.2.1 Cell Line 5.3.2.2Repoter gene 5.3.2.3 Media 5.3.3 Kit 6. Global GPCR Agonist Market Analysis, By Technology 6.1. Y-o-Y Growth Comparison, By Technology 6.2. Global GPCR Agonist Market Share Analysis, By Technology 6.3. Global GPCR Agonist Market Size and Forecast, By Technology 6.3.1High Throughput Functional Cell Based Assay 6.3.2 Fluorescence Microscopy Analysis 6.3.3 Triple-quadrupole mass spectroscopy 6.3.4 Luciferase Assay 6.3.5 Real Time Bioluminescence Resonance Energy Transfer (BRET) Assay 6.3.6 Reporter Gene Assay 6.3.7 cAMP Assay 6.3.8 cGMP Assay 6.3.9 High Throughput Screening (HTS) Assay 7. Global GPCR Agonist Market Analysis, By Application 7.1. Y-o-Y Growth Comparison, By Application 7.2. Global GPCR Agonist Market Share Analysis, By Application 7.3. Global GPCR Agonist Market Size and Forecast, By Application 7.3.1 Cancer Research 7.3.2 Cardiovascular System Diseases 7.3.3 Central Nervous System (CNS) Diseases 7.3.4 Immune System Diseases 7.3.5 Other Therapeutic Areas 7.3.6 Drug Discovery 8. Global GPCR Agonist Market Analysis, By End User 8.1. Y-o-Y Growth Comparison, By End User 8.2. Global GPCR Agonist Market Share Analysis, By End User 8.3. Global GPCR Agonist Market Size and Forecast, By End User 8.3.1 Academic Institutes & Research institutes 8.3.2 Clinical Research Organizations 8.3.3 Biopharmaceutical Companies 9. Global GPCR Agonist Market Analysis, By Region 9.1. Y-o-Y Growth Comparison, By Region 9.2. Global GPCR Agonist Market Share Analysis, By Region 10. North America GPCR Agonist Market Analysis and Forecast (2017-2030) 10.1 Introduction 10.2 North America GPCR Agonist Market Analysis, By Product Type 10.3 North America GPCR Agonist Market Analysis, By Technology 10.4 North America GPCR Agonist Market Analysis, By Application 10.5 North America GPCR Agonist Market Analysis, By End User 10.6 North America GPCR Agonist Market Analysis, By Country 10.6.1 USA 10.6.2 Canada 10.6.3 Mexico 11. Europe GPCR Agonist Market Analysis and Forecast (2017-2030) 11.1 Introduction 11.2 Europe GPCR Agonist Market Analysis, By Product Type 11.3 Europe GPCR Agonist Market Analysis, By Technology 11.4 Europe GPCR Agonist Market Analysis, By Application 11.5 Europe GPCR Agonist Market Analysis, By End User 11.6 Europe GPCR Agonist Market Analysis, By Country 11.6 .1 Germany 11.6 .2 France 11.6 .3 UK 11.6 .4 Rest of Europe 12. Asia Pacific GPCR Agonist Market Analysis and Forecast (2017-2030) 12.1 Introduction 12.2 Asia Pacific GPCR Agonist Market Analysis, By Product Type 12.3 Asia Pacific GPCR Agonist Market Analysis, By Technology 12.4 Asia Pacific GPCR Agonist Market Analysis, By Application 12.5 Asia Pacific GPCR Agonist Market Analysis, By End User 12.6 Asia Pacific GPCR Agonist Market Analysis, By Country 12.6.1 China 12.6.2 India 12.6.3 Japan 12.6.4 Rest of Asia Pacific 13. Latin America GPCR Agonist Market Analysis and Forecast (2017-2027) 13.1 Introduction 13.2 Latin America GPCR Agonist Market Analysis, By Product Type 13.3 Latin America GPCR Agonist Market Analysis, By Technology 13.4 Latin America GPCR Agonist Market Analysis, By Application 13.54 Latin America GPCR Agonist Market Analysis, By End User 14. Middle East & Africa GPCR Agonist Market Analysis and Forecast (2017-2027) 14.1 Introduction 14.2 Middle East & Africa GPCR Agonist Market Analysis, By Product Type 14.3 Middle East & Africa GPCR Agonist Market Analysis, By Technology 14.4 Middle East & Africa GPCR Agonist Market Analysis, By Application 14.5 Middle East & Africa GPCR Agonist Market Analysis, By End User 15. Competition Analysis 15.1 Competition Dashboard 15.2 Market Share Analysis of Top Vendors 15.3 Key Development Strategies 16. Company Profiles 16.1 European Collection of Cell Culture 16.1.1 Overview 16.1.2 Offerings 16.1.3 Key Financial 16.1.4 Business Segment & Geographic Overview 16.1.5 Key Market Developments 16.1.6 Key Strategies 16.2 Clontech Laboratries, Inc. 16.3 Nacalai Tesque 16.4 GE Healthcare 16.5 Thermo Fisher Scientific 16.6 Nano-Glo™ 16.7 Luciferase Assay System, 16.8 Promega 16.9 Ascent, Sigma-Aldrich 16.10 Wako Pure Chemical Industries 16.11 Zymo Research 16.12 Clontech Laboratries, Inc 16.13 Drummond Scientific Co
